Kala Pharmaceuticals Inc (KALA) stock has fallen 0.58% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.
Kala Pharmaceuticals Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on KALA!
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With KALA Stock Today?
Kala Pharmaceuticals Inc (KALA) stock has gained 1.18% while the S&P 500 is down -0.12% as of 11:18 AM on Wednesday, Dec 8. KALA is up $0.02 from the previous closing price of $1.70 on volume of 124,297 shares. Over the past year the S&P 500 is up 26.79% while KALA is down -76.76%. KALA lost -$2.04 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Kala Pharmaceuticals Inc click here.
More About Kala Pharmaceuticals Inc
Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of
therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases.
AMPPLIFY particles are selectively-sized nanoparticles and have proprietary coatings. It has applied the AMPPLIFY technology to create nanosuspensions
of loteprednol etabonate, or LE, acorticosteroid designed for ocular applications, resulting in two product candidates. INVELTYS was approved in August 2018
for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25 per cent is in Phase 3 development for the temporary relief of the signs and symptoms of dry eye disease.
Click Here to get the full Stock Report for Kala Pharmaceuticals Inc stock.